Segment Disclosures

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

Segment Disclosures

16. Segment Disclosures

We have aggregated our operations into two reportable segments based upon product lines, manufacturing processes, marketing and management of our businesses: medical equipment and radiopharmaceuticals.  Our business segments operate in the nuclear medicine industry. The Company’s medical equipment segment is currently generating all revenues and the majority of all expenses as the radiopharmaceuticals segment is still in the development phase.

We evaluate a segment’s performance based primarily upon operating income before corporate expenses.

Corporate assets consist primarily of cash but also include plant and equipment associated with our headquarters. These items (and income and expenses related to these items) are not allocated to the segments. Unallocated income/expenses include interest income, interest expense, debt extinguishment and refinancing costs and other (expense) income and certain expenses which are not considered related to either segment, but are instead considered general corporate expenses.

The following table represents sales, operating loss and total assets attributable to these business segments for the periods indicated (in thousands):

	Three Months Ended
	March 31, 2013			March 31, 2012
Total Sales:
Medical equipment	$	371		$	829
Radiopharmaceuticals		-			-
Total sales	$	371		$	829
Operating Loss:
Medical equipment	$	(582	)	$	(1,494	)
Radiopharmaceuticals		(187	)		(328	)
Unallocated		-			20
Total operating loss	$	(769	)	$	(1,802	)
Total Assets:
Medical equipment	$	1,629		$	2,591
Radiopharmaceuticals		914			1,054
Unallocated		-			3
Total assets	$	2,543		$	3,645